Bullish Case: Known: GLOW2 Phase 3 met primary endpoint; inferred: credibility for Zenkuda multi-indication BLA. KOD IV is in contango and slightly lower near-the-money on the vol-surface, implying room for upside without extreme repricing. Historical return likelihood concentrates around ~+25% over multi-year holds. If the market sees near-term FDA filing clarity, a grind from ~$37 toward $45–$55 looks statistically plausible.

Bearish Case: Known: put volume modestly exceeds calls and far-wing strikes carry the highest IV, signaling tail hedging. KOD’s long-dated contango suggests uncertainty extending past the GLOW2 event. The return surface still allows large negative outcomes (down to ~-86% in the sampled history). If FDA timelines slip or financing/dilution appears, IV could re-skew and price drift back toward the low-$30s.

Potential Outcomes:

1. 35%: FDA accepts/multi-indication filing (KOD contango + bullish risk) → +15–35%.
2. 20%: IV crush/digestion after GLOW2 → -5–+10%.
3. 20%: dilution/ATM terms (put-heavy hedging) → -15–30%.
4. 15%: macro shock (SPY vol↑) → -10–25%.
5. 10%: DAYBREAK/PEAK beat → +25–60%.

March 28, 2026